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OBJECTIVE — Recently, the American Diabetes Association (ADA) introduced new diag-
nostic criteria. These new criteria are based on fasting plasma glucose levels, avoiding the bur-
densome oral glucose tolerance test (OGTT). We compared the 1997 ADA criteria with the
1985 World Health Organization (WHO) criteria with respect to the prevalence of diabetes and
the cardiovascular risk profile in the population of the Hoorn Study.
RESEARCH DESIGN AND METHODS— The Hoorn Study is a population-based sur-
vey of 2,484 men and women, aged 50-75 years. An OGTT was performed and cardiovascu-
lar risk factors were determined in 2,378 subjects without known diabetes. Subjects were
categorized according to both sets of diagnostic criteria.
RESULTS — Although the prevalence of diabetes was similar for both sets of criteria, 47 of
120 (39.2%) subjects who were diagnosed with diabetes according to the 1997 ADA criteria
were not classified as having diabetes when using the 1985 WHO criteria. Similarly, of 285 sub-
jects diagnosed with impaired fasting glucose by the 1997 ADA criteria, 195 (68.4%) were clas-
sified as having normal glucose tolerance by the 1985 WHO criteria. The overall agreement was
poor (K 0.33; 95% CI 0.28-0.38). Subjects who were diagnosed as having diabetes by either
set of criteria had an adverse cardiovascular risk profile, which was between the cardiovascu-
lar risk profiles of concordant normal and concordant diabetic subjects.
CONCLUSIONS — In this study, both sets of criteria diagnosed a similar number of dia-
betic subjects, but many of the subjects shifted between glucose intolerance categories. With
either set of criteria, a considerable number of subjects at risk of developing diabetes and sub-
jects carrying an increased risk of cardiovascular disease, as reflected by an adverse cardiovas-
cular risk profile, will be missed.
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A table elsewhere in this issue shows conventional and Systeme International (SI) units and conversion
factors for many substances.
The most widely used diagnostic criteriafor glucose intolerance are those of theWorld Health Organization (WHO)(1). These criteria, published in 1985, are
based on fasting plasma glucose (FPG) val-
ues and glucose values measured 2 h after a
standard 75-g glucose load (2-h plasma glu-
cose [PG]) (Table 1). The cutoff points for
these diagnostic criteria are based mainly on
the prevalence of microvascular complica-
tions, in particular, retinopathy In 1995, an
international expert committee working
under the sponsorship of the American Dia-
betes Association (ADA) was established to
review the scientific literature since 1979,
and to decide whether changes in the diag-
nostic criteria for diabetes were required.
Recently, this committee introduced new
diagnostic criteria, which were subse-
quently endorsed by the ADA (2). These
new diagnostic criteria, published in 1997,
are based on FPG only, providing a more
simple test for diagnosing diabetes (Table
1). Because of its inconvenience to patients
and the perception by many physicians that
the oral glucose tolerance test (OGTT) is not
necessary, the OGTT is at present rarely
used for diagnosing diabetes in clinical
practice (3). Furthermore, concerning the
prevalence of microvascular complications,
several studies have shown that measure-
ment of 2-h PG values did not contribute
additional information to the predictive
value of FPG (4,5). One major complication
of glucose intolerance is macrovascular dis-
ease (6-8). By lowering the FPG value, the
diagnosis of diabetes in clinical practice is
expected to occur at an earlier stage of the
disease (9). This will most likely also affect
the cardiovascular risk factors in the various
glucose intolerance groups. Therefore, we
compared the 1997 ADA criteria with the
1985 WHO criteria with respect to the
prevalence of diabetes and the cardiovascu-
lar risk profile in a population-based study
of 2,378 men and women, aged 50-75
years, without previously known diabetes.
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Table 1—Diagnostic criteria for glucose intolerance according to WHO and ADA
1985 WHO criteria (1)
Diabetes
IGT
NGT
1997 ADA criteria (2)
Diabetes
1FG
NFG
FPG (mmol/1)
>7.8
<7.8
<7.8
>7.0
6.1-7.0
<6.1
or
and
and
2-h PG (mmol/1)
>11.1
7.8-11.1
<7.8
—
—
—
RESEARCH DESIGN AND
METHODS
Study population
The Hoorn Study is a survey of glucose
intolerance in a general Dutch population.
The study population and research design
have been described in detail previously
(10). In summary, 3,553 men and women,
aged 50-75 years, were randomly selected
from the population register of the middle-
sized Dutch town of Hoorn. Of the 2,540
subjects (71.5%) who agreed to partici-
pate, 56 non-Caucasians were excluded.
Therefore, the study cohort consisted of
2,484 men and women. All subjects gave
their informed written consent. The study
was approved by the ethics committee of
the Vrije Universiteit Academic Hospital.
Glucose intolerance
Before the physical examination, a fasting
blood sample was taken from all subjects.
Subsequently, an oral 75-g glucose load
was given. FPG and 2-h postload PG levels
were determined with a glucose dehydro-
genase method (Merck, Darmstadt, Ger-
many). Subjects were classified according
to both the 1985 WHO criteria (1) and the
1997 ADA criteria (2) (Table 1). Subjects
who were already using insulin, glucose-
lowering agents, or a diet for diabetes were
classified as having "known diabetes" (n =
90). This group was excluded from all
analyses. We also excluded 16 subjects for
whom information on the PG values was
missing. Consequently, all analyses were
done in the remaining study population of
2,378 subjects.
Examinations
Blood pressure was measured twice, using a
random-zero sphygmomanometer (Hawks-
ley-Gelman, Lancing, U.K.), on the right
arm with subjects sitting in a chair. The
average of duplicate measurements was used
for analyses. Subjects were considered
hypertensive when systolic blood pressure
(sBP) was ^ 1 6 0 mmHg, diastolic blood
pressure was ^ 9 5 mmHg, or when using
antihypertensive medication (11). Weight
and height were measured with subjects
wearing underwear only, and BMI was cal-
culated as the ratio of weight and height
squared. Waist and hip circumferences were
measured according to a standardized pro-
cedure (12). Waist-to-hip ratio (WHR) was
defined as waist circumference divided by
hip circumference. Triglycerides (TGs), total
cholesterol, and HDL cholesterol were deter-
mined from fasting blood samples by enzy-
matic techniques (Boehringer Mannheim,
Mannheim, Germany). The Friedewald for-
mula was used to calculate the level of LDL
cholesterol (13). Glycated hemoglobin
(HbAlc) was determined by ion-exchange
high-performance liquid chromatography
using a modular diabetes monitoring system
(Bio-Rad, Veenendaal, The Netherlands;
normal range 4.3-6.1%). Fasting specific
insulin level was quantified with an insulin-
specific double-antibody radioimmunoas-
say (antibody SP21; Linco, St. Louis, MO).
Information on smoking habits was
obtained by a translated questionnaire from
the London School of Hygiene (14).
Statistical methods
Prevalences of glucose intolerance were cal-
culated for both sets of diagnostic criteria.
To examine the agreement between the two
sets of criteria, a cross-table was made. The
overall K, which measures the agreement
across all categories of glucose intolerance,
was calculated. A value of 1 indicates per-
fect agreement, while a value of 0 indicates
that agreement is no better than chance.
Values >0.75 may be taken to represent
excellent agreement, values <0.40 may be
taken to represent poor agreement, and
values between 0.40 and 0.75 may be
taken to represent fair to good agreement
(15). Cardiovascular risk factors and meta-
bolic characteristics were compared among
several concordant and discordant glucose
intolerance groups. Differences among
these groups were tested with analysis of
covariance for continuous variables and
with logistic regression for proportions,
adjusted for age and sex. All analyses were
performed using the Statistical Package for
the Social Sciences (SPSS) for Windows
6.1 (16). P values were based on two-sided
tests, and the cutoff point for statistical sig-
nificance was 0.05.
RESULTS
Glucose intolerance
The study population consisted of 1,102
men with a mean age of 61.2 ± 7.3 years and
1,276 women with a mean age of 61.8 ± 7.4
years. All subjects were categorized accord-
ing to both the 1997 ADA criteria and the
1985 WHO criteria. The overall prevalence
of diabetes did not differ between the two
sets of criteria: 120 vs. 118 subjects were
diagnosed with diabetes using the 1997
ADA and the 1985 WHO criteria, respec-
tively (both 5%) (Table 2). However, of the
118 subjects diagnosed with diabetes
according to the 1985 WHO criteria, only
73 (61.9%) were also diagnosed with dia-
betes according to the 1997 ADA criteria. Of
the 45 subjects (38.1%) not diagnosed with
diabetes by the latter criteria, 26 were classi-
fied as having impaired fasting glucose (IFG)
and 19 were classified as having normal
Table 2—Agreement between the 1985 WHO criteria and the 1997 ADA criteria for glucose
intolerance in a population without known diabetes: the Hoorn Study
NGT (WHO) IGT (WHO) Diabetes (WHO) Total
NFG (ADA)
IFG (ADA)
Diabetes (ADA)
Total
1,791
195
22
2,008
163
64
25
252
19
26
73
118
1,973
285
120
2,378
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Table 3—Glycemic parameters and various cardiovascular risk factors for the concordant and discordant diabetic subgroups according to the
1985 WHO criteria and the 1997 ADA diagnostic criteria
n
FPG (mmol/1)
2-h PG (mmol/1)
Fasting specific insulin (pmol/1)
HbAlc (%)
Age (years)
Sex (% men)
sBP (mmHg)
Hypertension (%)
BMI (kg/m2)
WHR
Cholesterol (mmol/1)
HDL cholesterol (mmol/1)
LDL cholesterol (mmol/1)
TG (mmol/1)
Current smokers (%)
No diabetes (WHO)/
No diabetes (ADA)
2,213
5.4 ±0.5
5.6 ±1.7
75.5(56.1, 103.7)
5.3 ±0.5
61.3 ±7.3
46.1
134.1 ±19.7
28.6
26.3 ±3.4
0.89 ± 0.09
6.66 ±1.18
1.34 ±0.37
4.63 ±1.11
1.30(0.90,2.00)
48.4
Diabetes (WHO)/
No diabetes (ADA)
45
6.1±0.6*t
12.5 ± 1.4*t
107.6* (71.7, 166.3)
5.7 ±0.5*
65.5±6.3*t
40.0
148.5 ±19.3*
64.4*
28.2 ±4.1*
0.94±0.08*t
6.67 ±1.25
1.25 ±0.33*
4.48 ±1.16
1.80* (1.10,2.70)
33.3
No diabetes (WHO)/
Diabetes (ADA)
47
7.2±0.2*f
8.1 ± 1.9*1=
99.0* (70.6, 130.3)
5.8 ±0.5*
61.8 ±7.2=*
55.3
149.5 ±24.7*
55.3*
28.1 ±3.6*
0.93±0.08*f
6.74 ±1.12
1.25 ±0.30
4.67 ±0.99
1.60* (1.02, 2.44)
32.4
Diabetes (WHO)/
Diabetes (ADA)
73
9.6 ±3.3*
16.7 ±6.4*
112.2* (73.2, 158.5)
7.3 ±2.0*
65.8 ±7.0*
50.7
145.7 ±19.8*
52.1*
28.8 ±4.2*
0.96 ± 0.09*
6.67 ±1.45
1.13 ±0.32*
4.37 ±1.34*
2.20* (1.38,3.12)
45.5
Data are means ± SD, median (20th, 80th percentile), or %. TGs and fasting specific insulin are tested with log-transformed data. * Significantly different from 2,213
concordant nondiabetic subjects (age- and sex-adjusted, two-sided, P < 0.05); tsignificantly different from 47 subjects diagnosed as having diabetes according to
the ADA criteria only (age- and sex-adjusted, two-sided, P < 0.05); {significantly different from 45 subjects diagnosed as having diabetes according to the WHO
criteria only (age- and sex-adjusted, two-sided, P < 0.05).
fasting glucose (NFG). Similarly, 47 of 120
(39.2%) subjects who were diagnosed as
having diabetes according to the 1997 ADA
criteria were not diagnosed as having dia-
betes by the 1985 WHO criteria. By using
the 1997 ADA criteria, 285 subjects (12.0%)
were classified as having IFG, compared
with 252 subjects (10.6%) classified as hav-
ing impaired glucose tolerance (IGT) by the
1985 WHO criteria. A total of 163 subjects
(64.7%) categorized as having IGT by the
latter criteria were classified as having NFG
by the 1997 ADA criteria. Overall, the per-
centage of agreement between the two diag-
nostic criteria was 81%; 450 subjects (19%)
shifted among glucose intolerance groups.
The overall K was 0.33 (95% CI 0.28-0.38),
indicating poor agreement (15).
Cardiovascular risk profile
Glycemic parameters and some cardiovas-
cular risk factors were compared among
concordant diabetic subjects, both discor-
dant categories, and concordant nondiabetic
subjects (Table 3). FPG, 2-h PG, insulin, and
HbAlc values were significantly higher for
the discordant and concordant diabetic sub-
jects compared with the concordant nondi-
abetic subjects (P < 0.05). The subjects in
these diabetic groups were also more often
hypertensive and had higher values of BMI
and WHR compared with the concordant
nondiabetic subjects (P < 0.05).
The cardiovascular risk profile of sub-
jects who were diagnosed as having diabetes
by only one set of criteria was between the
cardiovascular risk profiles of concordant
nondiabetic and concordant diabetic sub-
jects. We also compared both discordant
categories with each other. Compared with
the 47 subjects classified as having diabetes
according to the 1997 ADA criteria only, the
45 subjects who were classified as having
diabetes by only the 1985 WHO criteria
had—as a consequence of the definition—
lower FPG, significantly higher 2-h PG
(12.5 vs. 8.1 mmol/1; P < 0.05), and higher
fasting insulin (median 107.6 vs. 99.0; P =
0.19). The subjects were also older (65.5 vs.
61.8 years; P < 0.05) and had higher
WHRs (0.94 vs. 0.93; P < 0.05).
Table 4 shows glycemic parameters and
some cardiovascular risk factors for the con-
cordant normal subjects, concordant
IGT/IFG subjects, and the discordant cate-
gories IGT/NFG and normal glucose toler-
ance (NGT)/IFG (both WHO/ADA criteria).
Compared with the concordant normal
subjects, FPG, 2-h PG, insulin, and HbAlc
were significantly higher for the two dis-
cordant categories and concordant IGT/IFG
subjects (P < 0.05). Also, these groups had
a more adverse cardiovascular risk profile
compared with the concordant NGT/NFG
group. Comparing the two discordant cate-
gories, the 163 subjects classified as having
IGT according to the WHO criteria only
had—as could be expected from the defin-
ition—lower FPG (5.6 vs. 6.3 mmol/1; P <
0.05), higher 2-h PG (8.9 vs. 5.8 mmol/1; P
< 0.05), and lower serum insulin (median
85.4 vs. 92.7 pmol/1; P < 0.05) compared
with the 195 subjects classified as having
IFG according to the ADA criteria only. The
subjects were also significantly older, were
more often women, and had lower HDL
cholesterol and higher TG levels (P < 0.05).
When the two sets of diagnostic criteria
were compared with respect to the identifi-
cation of newly diagnosed diabetes plus
IGT or IFG, more cases were found when
using the ADA criteria (405 vs. 370). The
cardiovascular risk profiles of these two
groups were very similar (data not shown).
CONCLUSIONS
Glucose intolerance
In this study of 2,378 men and women with
a mean age of 61.6 years, we analyzed the
consequences of using the 1997 ADA crite-
ria and the 1985 WHO criteria with respect
to the prevalence of glucose intolerance and
some cardiovascular risk factors. Compared
with classification according to the 1985
WHO criteria, 18.9% of all subjects shifted
to another glucose intolerance group when
applying the 1997 ADA criteria, without
affecting the overall prevalence of diabetes.
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Table 4—Glycemic parameters and various cardiovascular risk factors for the concordant and discordant IGT subgroups according to the 1985
WHO criteria and the 1997 ADA diagnostic criteria
n
FPG (mmol/1)
2-h PG (mmol/1)
Fasting specific insulin (pmol/1)
HbAlc (%)
Age (years)
Sex (% men)
sBP (mmHg)
Hypertension (%)
BMI (kg/m2)
WHR
Cholesterol (mmol/1)
HDL cholesterol (mmol/1)
LDL cholesterol (mmol/1)
TG (mmol/1)
Current smokers (%)
NGT (WHCO/NFG (ADA)
1,791
5.3 ±0.4
5.1 ±1.2
73.2 (55.3, 98.0)
5.3 ±0.5
60.8 ±7.2
45.3
132.0 ±19.2
25.6
26.0 ±3.3
0.88 ± 0.08
6.64 ±1.19
1.35 ±0.37
4.63 ± 1.12
1.30(0.90,1.90)
49.9
IGT (WHOVNFG (ADA)
163
5.6±0.4*t
8.9±0.9*t
85.4*t (56.5, 128.3)
5.5 ±0.5*
65.1±7.1*t
38.7T
142.6 ±19.4*
42.3*
27.4 ±3.6*
0.91 ±0.08*
6.73 ±1.20
1.27±0.36*t
4.59 ± 1.07
1.70*t (1.20, 2.50)
34.8*
NGT (WHOVIFG (ADA)
195
6.3±0.2*f
5.8±1.2*f
92.7** (70.7, 123.3)
5.5 ±0.5*
61.9 ±6.8**
58.5**
142.2 ± 16.8*
37.4*
27.4 ±3.7*
0.93 ± 0.08*
6.77 ±1.08*
1.32 ±0.371=
4.72 ± 1.06
1.50*^(1.10,2.10)
44.6
IGT (WHOVIFG (ADA)
64
6.4 ± 0.3*
9.1 ±0.9*
96.8* (65.5, 141.7)
5.7 ±0.5 *
64.4 ±8.1*
50.0
148.2 ± 24.8*
51.6*
28.3 ± 3.6*
0.94 ± 0.08*
6.76 ± 1.01
1.21 ±0.30*
4.66 ± 0.93
1.70* (1.20,2.40)
47.5
Data are means ± SD, median (20th, 80th percentile), or %. TGs and fasting specific insulin are tested with log-transformed data. Concordant and discordant
diabetic subjects were excluded in this table (n = 165). *Significantly different from 1,791 concordant normal subjects (age- and sex-adjusted, two-sided, P < 0.05);
tsignificantly different from 195 subjects diagnosed as having IFG according to the ADA criteria only (age- and sex-adjusted, two-sided, P < 0.05); ^significantly
different from 163 subjects diagnosed as having IGT according to the WHO criteria only (age- and sex-adjusted, two-sided, P < 0.05).
However, 38.1% of the subjects diagnosed
as having diabetes by the WHO criteria were
classified as either IFG or as NFG by the
ADA criteria. Also, 39.2% of the subjects
diagnosed as having diabetes according to
the ADA criteria were not diagnosed as hav-
ing diabetes by the WHO criteria.
The threshold for FPG has been low-
ered to 7.0 mmol/1 by the ADA, because of
the assumption that using the FPG crite-
rion alone should result in the diagnosis of
a similar number of patients as that diag-
nosed using the 1985 WHO criteria, which
is based on FPG and 2-h PG values
together (2,4,5,17-20). However, in our
study population, the agreement between
the 1997 ADA criteria and the 1985 WHO
criteria was poor, as reflected in the overall
K of 0.33 (15). Because the study popula-
tion was a random selection from the pop-
ulation registry of Hoorn, we can exclude
selection bias.
FPG and 2-h PG in this population
were assessed only once. In a subpopulation
of 1,109 subjects, a second OGTT was per-
formed after 2-6 weeks. As we previously
reported, the intra-individual coefficient of
variation was 6.5% for FPG and 16.7% for
2-h PG, indicating that the variability of 2-
h PG is larger than that of FPG (21). This
variability may have caused some random
misclassification in glucose intolerance cat-
egories. In this subpopulation, with
repeated measurements, when the diagnos-
tic criteria of the ADA and the WHO were
applied to the means of the duplicate FPG
and 2-h PG values, an overall K of 0.43
(95% CI 0.37-0.48) was observed, indicat-
ing fair to good agreement (15). So dupli-
cate measurements improve agreement.
Harris et al. (9) recently studied the
consequences of using the 1997 ADA cri-
teria on the prevalence of diabetes in the
National Health and Nutrition Examina-
tion Survey (NHANES) III population.
They found a prevalence of undiagnosed
diabetes of 4.4% by using the 1997 ADA
criteria and of 6.4% by using the 1985
WHO criteria, but they did not comment
on the fact that, overall, a large proportion
of all subjects shifted between categories. In
agreement with our findings, in the
NHANES III study, 46.9% of subjects clas-
sified as having diabetes according to the
1985 WHO criteria were classified as either
normal or having IFG by the 1997 ADA
criteria, and 22.7% of the subjects classified
as having diabetes according to the ADA
criteria were not classified as having dia-
betes by the WHO criteria.
In both the Hoorn Study and the
NHANES III study, a substantial number of
subjects shifted between IGT/IFG and nor-
mal. Nijpels et al. (22), in a prospective
study in subjects with IGT over an average
period of 3 years, found that 2-h PG rather
than FPG was the most important predictor
of conversion to NIDDM (22). This obser-
vation has been confirmed in other studies
(23). Therefore, measurement of 2-h PG
may be very important when investigating
the pathogenesis of diabetes and for the
identification of subjects at risk for conver-
sion to diabetes. Conversion rates of sub-
jects with IFG have not yet been published.
Cardiovascular risk profile
The changes in glucose intolerance cate-
gories also influence the level of cardiovas-
cular risk factors. The main risk factors for
macrovascular complications of diabetes
are generally the same as those in the non-
diabetic population, but they are more
prevalent among subjects with abnormal
glucose tolerance. This phenomenon has
been attributed to the so-called insulin
resistance syndrome: a clustering of meta-
bolic disorders, including glucose intoler-
ance, obesity, hypertension, and lipid
abnormalities (24-26). It is well accepted
that guidelines for the treatment of dia-
betes should include target values for these
established cardiovascular disease (CVD)
risk factors (6,27-29). With either set of
criteria, a considerable number of subjects
who carry an increased risk of CVD, as
reflected by an adverse cardiovascular risk
profile, will be missed. This again demon-
strates that it does not suffice to screen
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subjects at risk for CVD on the basis of glu-
cose levels. The results of the present study
indicate no differences in cardiovascular
risk factors between newly diagnosed dia-
betic plus IGT or IFG subjects using either
criteria. Therefore, for CVD risk stratifica-
tion, the presence of cardiovascular risk
factors like hypertension and obesity may
be a reason to determine fasting glucose.
Subjects with several risk factors and IFG
might benefit from glucose-lowering
advice, primarily lifestyle interventions.
In conclusion, the major advantage of
the 1997 ADA criteria is that one only needs
to measure FPG. The OGTT may no longer
be needed for diagnosis, but it remains an
important tool in pathogenetic research. In
clinical practice, measurement of FPG only
may lead to improved detection of subjects
with previously undiagnosed diabetes and
IFG, as is reflected by the younger age of the
subjects diagnosed with diabetes and IFG
when using the 1997 ADA criteria. To
answer the question whether application of
the new criteria will result in earlier detec-
tion and lower mortality and morbidity,
prospective studies are needed.
References
1. World Health Organization: Diabetes Melli-
tus: Report of a WHO Study Group. Geneva,
World Health Org., 1985 (Tech. Rep. Set,
no. 727)
2. The Expert Committee on the Diagnosis
and Classification of Diabetes Mellitus:
Report of the Expert Committee on the
Diagnosis and Classification of Diabetes Mel-
litus. Diabetes Care 20 (Suppl. 1):1183-
1197,1997
3. Orchard TJ: From diagnosis and classifica-
tion to complications and therapy: DCCT
part II? Diabetes Care 17:326-338, 1994
4. McCance DR, Hanson RL, Charles MA,
Jacobsson LTH, Pettitt DJ, Bennett PH,
Knowler WC: Comparison of tests for gly-
cated haemoglobin and fasting and two-
hour plasma glucose concentrations as
diagnostic methods for diabetes. BMJ
308:1323-1328, 1994
5. Engelgau MM, Thompson TJ, Herman
WH, Boyle JP, Aubert RE, Kenny SJ, Badran
A, Sous ES, Ali MA: Comparison of fasting
and 2-hour glucose and HbAlc levels for
diagnosing diabetes: diagnostic criteria and
performance revisited. Diabetes Care
20:785-791, 1997
6. Klein R: Hyperglycemia and micro vascular
and macrovascular disease in diabetes. Dia-
betes Care 18:258-268, 1995
7. Beks PJ, Mackaay AJC, de NeelingJND, de
Vries H, Bouter LM, Heine RJ: Peripheral
arterial disease in relation to glycaemic level
in an elderly Caucasian population: the
Hoorn Study. Diabetologia 38:86-96,1995
8. Barrett-Connor E: Does hyperglycemia
really cause coronary heart disease? Dia-
betes Care 20:1620-1623, 1997
9. Harris MI, Eastman RC, Cowie CC, Flegal
KM, Eberhardt MS: Comparison of dia-
betes diagnostic categories in the U.S. pop-
ulation according to 1997 American
Diabetes Association and 1980-1985
World Health Organization diagnostic cri-
teria. Diabetes Care 20:1859-1862, 1997
10. Mooy JM, Grootenhuis PA, de Vries H,
Valkenburg HA, Bouter LM, Kostense PJ,
Heine RJ: Prevalence and determinants of
glucose intolerance in a Dutch Caucasian
population: the Hoorn Study. Diabetes Care
18:1270-1273,1995
11. Working Group on Risk and High Blood
Pressure: An epidemiological approach to
describing risk associated with blood pres-
sure levels: final report of the Working
Group on Risk and High Blood Pressure.
Hypertension 7:641-651, 1985
12. Seidell JC, Cigolini M, Charzewska J, Con-
taldo F, Ellsinger B, Bjomtorp P: Measure-
ment of regional distribution of adipose
tissue. In Obesity in Europe 1. Bjomtorp P,
Rossner S, Eds. London, Libbey, 1988, p.
351-359
13. Friedewald WT, Levy RI, Fredrickson DS:
Estimation of the concentration of low-
density lipoprotein cholesterol in plasma,
without use of the preparative ultracen-
trifuge. Clin Chem 18:499-502, 1972
14. Rose GA, Blackburn H, Gillum RE, Prineas
RJ: Cardiovascular Survey Methods. Geneva,
World Health Organization, 1982
15. Landis JR, Koch GG: The measurement of
observer agreement for categorical data.
Biometrics 33:159-174, 1977
16. Norusis MJ: SPSS for Windows 6.1. Chicago,
SPSS, 1990
17. Finch C¥, Zimmet PZ, Alberti KGMM: Deter-
mining diabetes prevalence: a rational basis
for the use of fasting plasma glucose con-
centrations. DiabetMed 7:603-610,1990
18. Modan M, Harris MI: Fasting plasma glu-
cose in screening for NIDDM in the U.S.
and Israel. Diabetes Care 17:436-439,1994
19. McCance DR, Hanson RL, Charles MA,
Jacobsson LTH, Pettitt DJ, Bennett PH,
Knowler WC: Which test for diagnosing dia-
betes? Diabetes Care 18:1042-1045,1995
20. McCance DR, Hanson RL, Pettitt DJ, Ben-
nett PH, Hadden DR, Knowler WC: Diag-
nosing diabetes mellitus: do we need new
criteria? Diabetologia 40:247-255, 1997
21. Mooy JM, Grootenhuis PA, de Vries H,
Kostense PJ, Popp-Snijders C, Bouter LM,
Heine RJ: Intra-individual variation of glu-
cose, specific insulin, and proinsulin con-
centration measured by two oral glucose
tolerance tests in a general Caucasian pop-
ulation: the Hoorn Study. Diabetologia
39:298-305, 1996
22. Nijpels G, Popp-Snijders C, Kostense PJ,
Bouter LM, Heine RJ: Fasting proinsulin
and 2-h postload glucose levels predict the
conversion to NIDDM in subjects with
impaired glucose tolerance: the Hoorn
Study. Diabetologia 39:113-118, 1996
23. Edelstein SL, Knowler WC, Bain RP, Andres
R, Barrett-Connor EL, Dowse GK, Haffner
SM, Pettitt DJ, Sorkin JD, Muller DC,
Collins VR, Hamman RF: Predictors of pro-
gression from impaired glucose tolerance to
NIDDM: an analysis of six prospective
studies. Diabetes 46:701-710, 1997
24. DeFronzo RA, Ferrannini E: Insulin resis-
tance: a multifaceted syndrome responsible
for NIDDM, obesity, hypertension, dyslipi-
demia, and atherosclerotic cardiovascular
disease. Diabetes Care 14:173-194, 1991
2 5. Haffner SM: The insulin resistance syndrome
revisited. Diabetes Care 19:275-277, 1996
26. Meigs JB, dAgostino RB, Wilson PWF,
Cupples A, Nathan DM, Singer DE: Risk
variable clustering in the insulin resistance
syndrome: the Framingham Offspring
Study. Diabetes 46:1594-1600, 1997
27. Stern MP, Haffner SM: Dyslipidemia in type
II diabetes: implication for therapeutic inter-
vention. Diabetes Care 14:1144-1159,1991
28. Eastman RC, Cowie CC, Harris MI: Undi-
agnosed diabetes or impaired glucose tol-
erance and cardiovascular risk. Diabetes
Care 20:127-128, 1997
29. Donahue RP, Orchard TJ: Diabetes mellitus
and macrovascular complications: an epi-
demiological perspective. Diabetes Care
15:1141-1155, 1992
1690 DIABETES CARE, VOLUME 21, NUMBER 10, OCTOBER 1998
